Neptune Appoints IR Firm for the U.S.
2010年9月20日 - 9:30PM
Neptune Technologies & Bioressources Inc. ("Neptune")
(Nasdaq:NEPT) (TSX-V:NTB) today announces that it has appointed
CEOcast, Inc. ("CEOcast") as investor relations ("IR") firm for the
United States ("U.S.").
Neptune has entered into an IR agreement with CEOcast on
September 15, 2010 to develop and implement a capital markets
program for U.S. (the "Agreement"). The Agreement is subject to
TSX-Venture approval.
"The addition of CEOcast to our IR team for the U.S. is an
important step toward our new fully integrated IR
strategy. Indeed, with exhaustive presence in North America,
we are confident we will achieve our goals, which are to increase
trading volume on NASDAQ and TSX-V as well as achieving a fair
market value representation for Neptune shares while increasing the
investment community awareness for Neptune," stated Andre Godin,
Vice-President, Administration & Finance.
CEOcast, Inc. is a leading New York-based investor relations
firm that is highly proactive and has developed proprietary
databases affording clients unique access to high net-worth and
micro-cap institutional investors. CEOcast's activities are
designed to drive liquidity and awareness of a public company's
stock. The firm's principals and employees have decades of
experience in the investor relations area, utilizing proven
strategies and proprietary distribution methods to help increase
awareness of its clients. CEOcast achieves this through the
extensive use of road shows, media exposure, the Internet, direct
mail and conference calls with both the retail and institutional
investment community.
The term of the IR Agreement is for an initial period of six
months. In addition to a fee of $7,500 per month, CEOcast has been
granted options to purchase an aggregate total of 50,000 common
shares of Neptune at a price of $2 per share. The options
will vest in equal amounts at the rate of 15% per quarter and have
a three-year term expiring on September 1, 2013.
Also, Neptune modified the terms of the agreement with Howard
Group announced on July 14, 2010. All the terms mentioned in
the press release remain the same to the exception that Howard
Group will not receive 150,000 warrants in Acasti Pharma Inc.
mentioned in the press release.
About Neptune Technologies & Bioressources
Inc.
Neptune is an industry-recognized leader in the innovation,
production and formulation of science-based and clinically proven
novel phospholipid products for the nutraceutical and
pharmaceutical markets. The Company focuses on growing consumer
health markets including cardiovascular, inflammatory and
neurological diseases driven by consumers taking a more proactive
approach to managing health and preventing disease. The Company
sponsors clinical trials aimed to demonstrate its product health
benefits and to obtain regulatory approval for label health claims.
Neptune is continuously expanding its intellectual property
portfolio as well as clinical studies and regulatory approvals.
Neptune's products are marketed and distributed in over 20
countries worldwide.
About Acasti Pharma Inc.
Acasti Pharma is developing a product portfolio of proprietary
novel long-chain omega-3 phospholipids. Phospholipids are the
major component of cell membranes and are essential for all vital
cell processes. They are one of the principal constituents of High
Density Lipoprotein (good cholesterol) and, as such, play an
important role in modulating cholesterol efflux. Acasti Pharma's
proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been
shown to have substantial health benefits and which are stabilized
by potent antioxidants. Acasti Pharma is focusing initially on
treatments for chronic cardiovascular conditions within the
over-the-counter, medical food and prescription drug markets.
About NeuroBioPharm Inc.
NeuroBioPharm is pursuing pharmaceutical neurological
applications, and a clinical study for a medical food product with
a multinational partner is already initiated. The development of a
prescription drug candidate is currently in progress. Advanced
clinical development and commercialization is planned to be carried
out with multinational partners.
"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release."
Statements in this press release that are not statements of
historical or current fact constitute "forward-looking statements"
within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995 and Canadian securities laws. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other unknown factors that could cause the
actual results of the Company to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. In addition to statements which
explicitly describe such risks and uncertainties, readers are
urged to consider statements labeled with the terms "believes,"
"belief," "expects," "intends," "anticipates," "will," or
"plans" to be uncertain and forward-looking. The forward-looking
statements contained herein are also subject generally to other
risks and uncertainties that are described from time to time in the
Company's reports filed with the Securities and Exchange Commission
and the Canadian securities commissions.
CONTACT: Neptune Technologies & Bioressources Inc.
Andre Godin, V.P. Administration and Finance
+1 450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com
CEOcast, Inc.
Jim Fallon
+1 212-732-4300
jfallon@ceocast.com
www.ceocast.com
Neptune Wellness Solutions (NASDAQ:NEPT)
過去 株価チャート
から 6 2024 まで 7 2024
Neptune Wellness Solutions (NASDAQ:NEPT)
過去 株価チャート
から 7 2023 まで 7 2024